- Home
- Publications
- Publication Search
- Publication Details
Title
Metastatic gastric cancer treatment: Second line and beyond
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 11, Pages 3069
Publisher
Baishideng Publishing Group Inc.
Online
2016-03-31
DOI
10.3748/wjg.v22.i11.3069
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
- (2015) Sylvie Lorenzen et al. EUROPEAN JOURNAL OF CANCER
- Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
- (2014) E Alba et al. BRITISH JOURNAL OF CANCER
- Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
- (2014) Yasutsuna Sasaki et al. CANCER SCIENCE
- A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)
- (2014) W. Koizumi et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Drug resistance to targeted therapies: Déjà vu all over again
- (2014) Floris H. Groenendijk et al. Molecular Oncology
- Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
- (2014) Roberto Iacovelli et al. PLoS One
- Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study
- (2013) J.A. Ajani et al. EUROPEAN JOURNAL OF CANCER
- Checkpoint blocking antibodies in cancer immunotherapy
- (2013) Chrisann Kyi et al. FEBS LETTERS
- Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
- (2013) Shuichi Hironaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial
- (2013) Jin Li et al. JOURNAL OF CLINICAL ONCOLOGY
- FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
- (2013) Marcello Maugeri-Saccà et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- Sequential Chemotherapies for Advanced Gastric Cancer: A Retrospective Analysis of 111 Patients
- (2013) Christoph Elsing et al. ONCOLOGY
- Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
- (2013) Min Jeong Lee et al. Cancer Research and Treatment
- Molecular Diagnosis for Personalized Target Therapy in Gastric Cancer
- (2013) Jae Yong Cho Journal of Gastric Cancer
- Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
- (2012) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy
- (2012) Sun Jin Sym et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
- (2012) Eun Joo Kang et al. Gastric Cancer
- Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
- (2012) Jung Hun Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin
- (2010) Rai Shimoyama et al. Gastric Cancer
- Trastuzumab for gastric cancer treatment
- (2010) Alicia FC Okines et al. LANCET
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Salvage Chemotherapy With Biweekly Irinotecan, Plus 5-Fluorouracil and Leucovorin in Patients With Advanced Gastric Cancer Previously Treated With Fluoropyrimidine, Platinum, and Taxane
- (2008) Sun Jin Sym et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now